{"authors": [["Tamez", "Rebecca L", "RL", "Department of Dermatology, Northwell Health System, New Hyde Park, NY, USA."], ["Tan", "Whitney V", "WV", "Department of Dermatology, Columbia University Medical Center, New York, NY, USA."], ["O'Malley", "John T", "JT", "Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA."], ["Broder", "Karen R", "KR", "Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, USA."], ["Garzon", "Maria C", "MC", "Department of Dermatology, Columbia University Medical Center, New York, NY, USA."], ["LaRussa", "Philip", "P", "Department of Pediatrics, Columbia University Medical Center, New York, NY, USA."], ["Lauren", "Christine T", "CT", "Department of Dermatology, Columbia University Medical Center, New York, NY, USA."]], "date": "2017-12-28", "id": "29282756", "text": "A 2-year-old boy with influenza B infection and rapidly worsening targetoid skin lesions with mucosal involvement was diagnosed with Stevens-Johnson syndrome (SJS) and treated with oseltamivir and intravenous immunoglobulin, with resolution of illness. Subsequent quadrivalent inactivated influenza vaccine was well tolerated. This case highlights the rarity of SJS in the setting of influenza B infection and addresses the safety of administering subsequent influenza vaccines to such individuals.", "doi": "10.1111/pde.13370", "title": "Influenza B virus infection and Stevens-Johnson syndrome.", "journal": ["Pediatric dermatology", "Pediatr Dermatol"]}